First Self-injectable HIV Antibody

There’s a new hope for those suffering from HIV infection: the first self-injectable antibody, PRO 140, developed by CytoDyn Inc., has documented a 98% success rate in a Phase 2b clinical trial for patients with HIV. In a monotherapy study, some HIV patients using PRO 140 are experiencing a completely suppressed viral load for about 11 months, according to the company. And PRO 140 could be commercialized in 2017 if it receives positive results from an upcoming Phase 3 trial.